BGI UK joins KYND’s Broker Programme to simplify and accelerate cyber insurance sales

KYND Limited, provider of pioneering cyber risk management products, today announced that specialist insurer BGI.UK has become a member of the recently launched KYND Broker Programme to help its broker members overcome the industry-specific challenges they’re facing when selling cyber policies and drive the sustainable growth of the cyber insurance market.

The exclusive KYND Broker Programme uses KYND’s pioneering cyber risk technology and insights to provide its members with unrivalled access to the cyber tools, resources, and 360-degree sales support that enables brokers to become cyber experts and provide the best information and advice to their clients, removing many of the obstacles faced when selling cyber insurance.

Andy Thomas, KYND’s CEO, comments: “We are delighted BGI.UK has joined the KYND Broker programme. As cyber risks continue to impact businesses, now more than ever, cyber insurance is a necessity, not a luxury. With our Broker Programme we aim to demystify cyber risk for both brokers and their clients by giving our members the tools and support to effectively meet the growing need for cyber insurance”.

Nick Elwell,’s CEO, adds: “We aim to give the best practical advice and service to our clients, but in a world where cyber risks are evolving and emerging daily, this presents ever-growing challenges. That’s why we’re absolutely delighted to join the KYND Broker Programme. For the first time, we can instantly access expert cyber insights in an easy to understand way that we can share with our clients and full support for our brokers throughout the sales process which is invaluable in ensuring we continue to deliver the ultimate service to our insureds”.

About KYND
Founded in March 2018 and headquartered in London, KYND is a new breed of cyber company. KYND makes complex cyber risks simple to understand and manage for every organisation, regardless of size, means or industry sector.

About is a privately owned, independent insurance broker regulated by the Financial Conduct Authority. Established in 1982, has developed a portfolio of clients throughout the UK who operate worldwide. Specialising in a variety of insurances ranging from complex commercial risks to everyday ‘home and contents’ offer bespoke, tailored insurance solutions to clients directly or as a wholesale broker imparting technical expertise and providing access to niche market areas.

– For more information about KYND visit
– For more information on BGI.UK, please visit www.

Source link

Quantib and Amsterdam UMC enter partnership to accelerate AI solutions, THE NETHERLANDS, October 11th, 2019 – Quantib, leader in Medical Imaging AI solutions, and Amsterdam UMC announce their partnership to develop and validate AI software in a joint venture with University Medical Center Utrecht, named Quantib-U. As part of the deal, Amsterdam UMC will provide access to data and allocate one of its top AI Medical Imaging scientists to projects within Quantib-U on a part-time basis. Quantib is now backed by the three largest radiology practices* of The Netherlands together providing unique insights into new use cases, broad data access and user feedback in a multi-center setting.

Truly successful adoption of new AI software will only happen if we co-create with top clinicians and AI researchers”, says Arthur Post Uiterweer, CEO of Quantib and Quantib-U. “ With this partnership it now only takes a few weeks to develop and deploy new AI prototypes for clinical validation in three top clinical centers.”

Amsterdam UMC is a top clinical center, the largest in The Netherlands, and very interested in the new options that AI developments provide in healthcare. Additionally, Amsterdam UMC is happy to establish this collaboration with Quantib, which will allow Amsterdam UMC, through its AI Medical Imaging team, to contribute to the creation of better solutions for the benefit of patients.

About Quantib

Quantib, a leader in medical AI software, strives for faster and more accurate diagnoses, supporting adequate and timely patient care. Its products can detect changes in tissue sooner than would be possible with the naked eye. Quantib has multiple products cleared by FDA and CE marked, which are focused on quantification of neurodegenerative disease. It has a strong pipeline of new products focused on oncology and osteoarthritis.

For more information:

About Amsterdam Medical Center

At Amsterdam UMC, more than 15,000 professionals strive to provide good and accessible care for the generations of today and tomorrow, working together towards a future in which we prevent illnesses and make the best treatment available to all patients. To this end, we develop new methods for diagnostics and treatment together with professionals from other renowned national and international institutions. We treat over 350,000 patients a year at both our sites – AMC and VUmc. Our main focus is on complex patient care and highly-specialized treatment of rare medical conditions. At Amsterdam UMC, we teach and train thousands of young people to become doctors, specialists or nurses. Our researchers are clustered in eight research centers so that we can achieve our ambition of executing international, cutting-edge research. At Amsterdam UMC, AMC and VUmc are working together on academic patient care, scientific research and teaching & training.

*Erasmus Medical Center and University Medical Center Utrecht joined Quantib earlier in a partnership.

Source link